收费全文 | 26666篇 |
免费 | 2333篇 |
国内免费 | 59篇 |
耳鼻咽喉 | 329篇 |
儿科学 | 817篇 |
妇产科学 | 543篇 |
基础医学 | 3871篇 |
口腔科学 | 423篇 |
临床医学 | 2807篇 |
内科学 | 5005篇 |
皮肤病学 | 431篇 |
神经病学 | 2686篇 |
特种医学 | 844篇 |
外科学 | 3727篇 |
综合类 | 823篇 |
现状与发展 | 1篇 |
一般理论 | 34篇 |
预防医学 | 2630篇 |
眼科学 | 648篇 |
药学 | 1717篇 |
1篇 | |
中国医学 | 48篇 |
肿瘤学 | 1673篇 |
2022年 | 269篇 |
2021年 | 495篇 |
2020年 | 285篇 |
2019年 | 471篇 |
2018年 | 534篇 |
2017年 | 377篇 |
2016年 | 444篇 |
2015年 | 517篇 |
2014年 | 636篇 |
2013年 | 1065篇 |
2012年 | 1474篇 |
2011年 | 1427篇 |
2010年 | 866篇 |
2009年 | 818篇 |
2008年 | 1368篇 |
2007年 | 1329篇 |
2006年 | 1249篇 |
2005年 | 1326篇 |
2004年 | 1318篇 |
2003年 | 1198篇 |
2002年 | 1138篇 |
2001年 | 611篇 |
2000年 | 618篇 |
1999年 | 561篇 |
1998年 | 314篇 |
1997年 | 248篇 |
1996年 | 227篇 |
1995年 | 225篇 |
1994年 | 170篇 |
1993年 | 217篇 |
1992年 | 430篇 |
1991年 | 398篇 |
1990年 | 422篇 |
1989年 | 402篇 |
1988年 | 378篇 |
1987年 | 344篇 |
1986年 | 357篇 |
1985年 | 377篇 |
1984年 | 293篇 |
1983年 | 234篇 |
1982年 | 225篇 |
1981年 | 223篇 |
1980年 | 193篇 |
1979年 | 188篇 |
1978年 | 168篇 |
1976年 | 175篇 |
1975年 | 148篇 |
1974年 | 202篇 |
1973年 | 153篇 |
1971年 | 152篇 |
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献Material and methods: original research studies were searched from seven databases (MEDLINE, EMBASE, CENTRAL, CINAHL, SCOPUS, PEDro and PubMed). Subsequently, two independent reviewers screened the titles and abstracts followed by full-text reviews to assess the studies' eligibility.
Results: eleven studies met the inclusion criteria and had data abstracted and quality assessed. Methodology varied considerably and yet cognitive tasks resulted in the ΔO2Hb increasing in 8 of the 11 and ΔHHb decreasing in 8 of 8 studies that reported this outcome. The cognitive tasks from 10 of the 11 studies were classified as “Working Memory” and “Verbal Fluency Tasks”.
Conclusions: although, the data comparison was challenging provided the heterogeneity in methodology, the results across studies were similar. 相似文献